EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Androgen receptor inhibition extends PARP inhibitor activity in prostate cancer models beyond BRCA mutations and defects in homologous recombination repair

Giuditta Illuzzi iD, Alessandro Galbiati, Anna D Staniszewska, Robert Hanson, Chrysiis Michaloglou, Sophie L Cooke, Karolina Uznańska, Maja Białecka, Kamil Solarczyk, Harveer S Dev, Charlie E Massie, Mark R Albertella und 3 weitere

NAR Cancer · 2025

DOI: 10.1093/narcan/zcaf035 ↗

Kurz gefasst

Fachartikel in der Zeitschrift NAR Cancer, 2025. Verfasst von Giuditta Illuzzi und 14 weiteren Autor:innen. Beteiligte Einrichtung: Bioscience, Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge CB2 0AA, UK. Hauptthemen laut MEDLINE: Poly(ADP-ribose) Polymerase Inhibitors, Recombinational DNA Repair, Receptors, Androgen, Androgen Receptor Antagonists. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: John Black Charitable Foundation, AstraZeneca UK, Cancer Research UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clinical trials show benefit of the combination of poly(ADP-ribose) polymerase inhibitors (PARPi) with androgen receptor (AR) pathway inhibitors (ARPi) in metastatic, castration-resistant prostate cancer. While benefit was evident in patients with tumours harbouring mutations in homologous recombination repair (HRR) genes, improved outcomes were also observed in the absence of such alterations. Although there is literature linking AR with DNA repair, the basis of the interaction between the AR and PARP is unclear. We show that benefit of the combination of ARPi and PARPi in prostate cancer models with no HRR mutations requires ARPi-responsive cells and a PARPi with PARP1-trapping activity, and does not involve an effect of PARPi treatment in modulating AR transcription. Combination benefit is driven by an increase in DNA double-strand breaks and micronuclei formation, which is not due to a control of HRR gene transcription by the AR. Also, we uncover a novel role of PARP1 modulating AR recruitment to chromatin in the presence of DNA damage. These data shed light on the interplay between PARP1 and the AR in dealing with genotoxic insults and provide a mechanism-of-action consistent with the clinical benefit of the combination of PARPi and ARPi in patients with prostate cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Poly(ADP-ribose) Polymerase InhibitorsRecombinational DNA RepairReceptors, AndrogenAndrogen Receptor AntagonistsProstatic Neoplasms, Castration-ResistantBRCA2 ProteinProstatic NeoplasmsBRCA1 ProteinMaleHumansMutationPoly (ADP-Ribose) Polymerase-1Cell Line, TumorDNA Breaks, Double-StrandedAnimalsMice

Substanzen

Poly(ADP-ribose) Polymerase InhibitorsReceptors, AndrogenPoly (ADP-Ribose) Polymerase-1Androgen Receptor AntagonistsPARP1 protein, humanAR protein, humanBRCA2 ProteinBRCA1 ProteinBRCA2 protein, humanBRCA1 protein, human

Autor:innen und Institutionen

  • Bioscience, Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge CB2 0AA, UK.
  • Translational Medicine, Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge CB2 0AA, Cambridge, UK.
  • Early Cancer Institute, Cancer Research UK Cambridge Centre; Department of Oncology, University of Cambridge Hutchison-MRC Research Centre, Adrian Way, Cambridge CB2 0AH, UK.
  • intoDNA S.A., Bobrzyńskiego 14, 30-348 Krakow, Poland.

ORCID-Profile: Giuditta Illuzzi, Josep V Forment, Mark J O'Connor

Förderung

  • John Black Charitable Foundation
  • AstraZeneca UK
  • Cancer Research UK
  • Prostate Cancer Foundation

Zitieren

APA

Illuzzi, G., Galbiati, A., Staniszewska, A. D., Hanson, R., Michaloglou, C., Cooke, S. L., Uznańska, K., Białecka, M., Solarczyk, K., Dev, H. S., Massie, C. E., Albertella, M. R., Leo, E., Forment, J. V., & O'Connor, M. J. (2025). Androgen receptor inhibition extends PARP inhibitor activity in prostate cancer models beyond BRCA mutations and defects in homologous recombination repair. NAR Cancer. https://doi.org/10.1093/narcan/zcaf035

Vancouver

Illuzzi G, Galbiati A, Staniszewska AD, Hanson R, Michaloglou C, Cooke SL, et al. Androgen receptor inhibition extends PARP inhibitor activity in prostate cancer models beyond BRCA mutations and defects in homologous recombination repair. NAR Cancer. 2025. doi:10.1093/narcan/zcaf035

BibTeX
@article{Illuzzi2025,
  author = {Illuzzi, Giuditta and Galbiati, Alessandro and Staniszewska, Anna D and Hanson, Robert and Michaloglou, Chrysiis and Cooke, Sophie L and Uznańska, Karolina and Białecka, Maja and Solarczyk, Kamil and Dev, Harveer S and Massie, Charlie E and Albertella, Mark R and Leo, Elisabetta and Forment, Josep V and O'Connor, Mark J},
  title = {Androgen receptor inhibition extends PARP inhibitor activity in prostate cancer models beyond BRCA mutations and defects in homologous recombination repair},
  journal = {NAR Cancer},
  year = {2025},
  doi = {10.1093/narcan/zcaf035}
}
Kostenlos starten →